GREENLAND MINES LTD Contingent Consideration Classified as Equity, Fair Value Disclosure
GREENLAND MINES LTD (GRML) had Contingent Consideration Classified as Equity, Fair Value Disclosure of $60.00 million as of 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure · last filed 2025-03-31
- 2024-12-31: Contingent Consideration Classified as Equity, Fair Value Disclosure $60.00M.
- 2024-09-30: Contingent Consideration Classified as Equity, Fair Value Disclosure $60.00M.
- 2024-06-30: Contingent Consideration Classified as Equity, Fair Value Disclosure $60.00M.
| Period end | Contingent Consideration Classified as Equity, Fair Value Disclosure |
|---|---|
| 2024-12-31 | $60.00M 10-K · filed 2025-03-31 |
| 2024-09-30 | $60.00M 10-Q · filed 2024-11-19 |
| 2024-06-30 | $60.00M 10-Q · filed 2024-08-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |